Results 291 to 300 of about 69,647 (307)

Effect of red wine on coronary flow-velocity reserve

Lancet, The, 1999
exaly  

Five-Year Outcomes with PCI Guided by Fractional Flow Reserve

New England Journal of Medicine, 2018
Panagiotis Xaplanteris, Stephane Fournier, William F Fearon   +2 more
exaly  

PET coronary flow reserve

2005
openaire   +1 more source

Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI

New England Journal of Medicine, 2017
Matthias Götberg, Lars Jakobsen, Elmir Omerovic   +2 more
exaly  

Excess Cardiovascular Risk in Women Relative to Men Referred for Coronary Angiography Is Associated With Severely Impaired Coronary Flow Reserve, Not Obstructive Disease

Circulation, 2017
Viviany R Taqueti, Leslee J Shaw, Venkatesh L Murthy   +2 more
exaly  

Quantitative flow ratio versus fractional flow reserve for coronary revascularisation guidance (FAVOR III Europe): a multicentre, randomised, non-inferiority trial

Lancet, The
Birgitte Krogsgaard Andersen, Truls Råmunddal, Ramon Lopez-Palop   +2 more
exaly  

Fractional Flow Reserve and Cardiac Events in Coronary Artery Disease

Circulation, 2017
Jung-Min Ahn, Duk-Woo Park, Eun-Seok Shin   +2 more
exaly  

Clinical Outcomes and Cost-Effectiveness of Fractional Flow Reserve–Guided Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease

Circulation, 2018
William F Fearon, Takeshi Nishi, Bernard De Bruyne   +2 more
exaly  

Outcomes after fractional flow reserve-guided percutaneous coronary intervention versus coronary artery bypass grafting (FAME 3): 5-year follow-up of a multicentre, open-label, randomised trial

Lancet, The
Joanna J Wykrzykowska, Zsolt Piroth, Bart van Straten   +2 more
exaly  

TransCatheter aortic valve implantation and fractional flow reserve-guided percutaneous coronary intervention versus conventional surgical aortic valve replacement and coronary bypass grafting for treatment of patients with aortic valve stenosis and complex or multivessel coronary disease (TCW): an international, multicentre, prospective, open-label, non-inferiority, randomised controlled trial

Lancet, The
Renicus Hermanides, Jerzy Sacha, Krzysztof P Malinowski   +2 more
exaly